Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.

News & Insights

Oxford Technology & Innovations EIS Fund (OTIF) subscribes to OrganOx Ltd’s £25m fundraise.

  • OrganOx has raised £25m to continue the development and commercial rollout of metra, its fully automated normothermic perfusion (NMP) device for liver transplantation.
  • The round was led by external investor Lauxera Capital Partners, with support from existing investors.

Oxford Investment Consultants LLP (OIC) is pleased to announce that the Oxford Technology & Innovations EIS Fund (OTIF) has subscribed to OrganOx Ltd’s £25m fundraise.

The investment will support expanding clinical adoption of the metra, particularly in the US market, alongside further investment in new infrastructure both in the UK and US to support ongoing progress of the R&D pipeline. The metra has already supported more than 2,500 successful liver transplants across Europe, the US and Australia, and clinical adoption continues to grow.

Craig Marshall, Chief Executive Officer, OrganOx said: “We are thrilled to have Lauxera Capital Partners at the table. Their collective experiences will be invaluable to OrganOx as we execute our commercial strategy in Europe, North America and Australia. OrganOx is committed to using our NMP technology to make organs more widely available to patients who need them around the world.”

Sam Levy, MD, Lauxera Capital Partners, added: “Lauxera is proud and honoured to back the OrganOx team and its global commercial scale-up. This is the ninth investment made by Lauxera Growth I, a growth buy-out fund dedicated to investing in commercial-stage European and North American HealthTech businesses.”

Read the full press release here.